John M. Leonard - 01 Mar 2026 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Reporting relationship: President and CEO, Director
Issuer ticker: NTLA
Reported as of: 01 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Mar 2026, 16:19:05 UTC
Prior SEC filing: 07 Jan 2026
Next SEC filing: 27 Apr 2026
Source filing: View source filing
Reporting owner signature: James Basta, attorney-in-fact

Key filing fact

John M. Leonard filed Form 4 for Intellia Therapeutics, Inc. (NTLA) on 03 Mar 2026.

Key facts

This page summarizes John M. Leonard's Form 4 filing for Intellia Therapeutics, Inc. (NTLA).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 03 Mar 2026, 16:19.

Change

Previous filing in this sequence was filed on 07 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001563584 Primary reporting owner

LEONARD JOHN M

Relationship: President and CEO, Director
Address: C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET; SUITE 130, CAMBRIDGE
Signature: James Basta, attorney-in-fact
Signature date: 03 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NTLA transaction

Common Stock

Award

Transaction value: $0
Shares: +156,400
Change %: +15%
Price: $0.000000
Shares after: 1,169,739
Date: 01 Mar 2026
Ownership: Direct
Footnotes: F1

NTLA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 58,415
Date: 01 Mar 2026
Ownership: By Trust
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NTLA transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +225,400
Change %
Price: $0.000000
Shares after: 225,400
Date: 01 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 225,400
Exercise price: $13.78
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

Footnote F2

Shares held by the John M. Leonard 2015 Irrevocable Trust.

Footnote F3

This option was granted on March 1, 2026 with respect to shares of Common Stock, with 33% vesting on January 1, 2027 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.